JP2016530239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530239A5 JP2016530239A5 JP2016525434A JP2016525434A JP2016530239A5 JP 2016530239 A5 JP2016530239 A5 JP 2016530239A5 JP 2016525434 A JP2016525434 A JP 2016525434A JP 2016525434 A JP2016525434 A JP 2016525434A JP 2016530239 A5 JP2016530239 A5 JP 2016530239A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- clostridium cluster
- bacteria
- butyrate
- flagellin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 20
- 241000193403 Clostridium Species 0.000 claims 15
- 241000894006 Bacteria Species 0.000 claims 12
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 5
- 108010040721 Flagellin Proteins 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000002708 enhancing effect Effects 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 210000005027 intestinal barrier Anatomy 0.000 claims 5
- 230000007358 intestinal barrier function Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000004666 short chain fatty acids Chemical class 0.000 claims 2
- 101710151190 Flagellin A Chemical class 0.000 claims 1
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 claims 1
- 101150103290 Hcar2 gene Proteins 0.000 claims 1
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- WFVFQUPBGWFLMB-DVYMNCLGSA-N [(3ar,5r,6s,6ar)-5-[(1r)-1,2-dihydroxyethyl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-yl] butanoate Chemical compound O1C(C)(C)O[C@@H]2[C@@H](OC(=O)CCC)[C@@H]([C@H](O)CO)O[C@@H]21 WFVFQUPBGWFLMB-DVYMNCLGSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000021391 short chain fatty acids Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844204P | 2013-07-09 | 2013-07-09 | |
| US61/844,204 | 2013-07-09 | ||
| PCT/US2014/045801 WO2015006355A2 (en) | 2013-07-09 | 2014-07-08 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019092447A Division JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530239A JP2016530239A (ja) | 2016-09-29 |
| JP2016530239A5 true JP2016530239A5 (enExample) | 2017-08-17 |
Family
ID=52280706
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525434A Pending JP2016530239A (ja) | 2013-07-09 | 2014-07-08 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| JP2019092447A Pending JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019092447A Pending JP2019189609A (ja) | 2013-07-09 | 2019-05-15 | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US9764019B2 (enExample) |
| EP (1) | EP3019181A4 (enExample) |
| JP (2) | JP2016530239A (enExample) |
| WO (1) | WO2015006355A2 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| AU2011286165B2 (en) | 2010-08-04 | 2016-10-20 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| BR112013022927A2 (pt) | 2011-03-09 | 2016-12-06 | Univ Minnesota | composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| EP3978598B1 (en) | 2011-12-01 | 2024-08-28 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| JP2016530239A (ja) * | 2013-07-09 | 2016-09-29 | ピュアテック ベンチャーズ、エルエルシー | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
| ES2755332T3 (es) | 2013-11-27 | 2020-04-22 | Epics Therapeutics | Compuestos, composición farmacéutica y métodos para su uso en el tratamiento de la inflamación |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| WO2016102950A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Immune modulation |
| HRP20180847T1 (hr) | 2014-12-23 | 2018-08-24 | 4D Pharma Research Limited | Pirinski polipeptid i imunološka modulacija |
| JP6783247B2 (ja) | 2015-01-23 | 2020-11-11 | テンプル ユニヴァーシティ − オブ ザ コモンウェルス システム オブ ハイアー エデュケーション | ガン予防における短鎖脂肪酸の使用 |
| KR20180026376A (ko) | 2015-05-14 | 2018-03-12 | 크레스토보 홀딩스 엘엘씨 | 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치 |
| DK3297644T3 (da) | 2015-05-22 | 2022-04-11 | Univ Arizona State | Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer |
| EP3662917A1 (en) | 2015-06-15 | 2020-06-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| PL3650033T3 (pl) | 2015-06-15 | 2022-05-16 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| RS59446B1 (sr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PL3209310T3 (pl) | 2015-11-20 | 2018-08-31 | 4D Pharma Research Limited | Kompozycja zawierająca szczepy bakteryjne |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| MD3313423T2 (ro) | 2016-03-04 | 2019-10-31 | 4D Pharma Plc | Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale |
| JP7168558B2 (ja) | 2016-06-14 | 2022-11-09 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CN110475551A (zh) * | 2017-01-27 | 2019-11-19 | 英联邦高等教育系统天普大学 | 使用短链脂肪酸治疗和预防疾病和障碍 |
| US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| WO2018187272A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| CN110831606A (zh) | 2017-04-05 | 2020-02-21 | 克雷斯顿沃控股公司 | 治疗帕金森氏病(pd)和相关疾病的组合物和方法 |
| WO2018195067A1 (en) | 2017-04-17 | 2018-10-25 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
| CA3064171A1 (en) | 2017-05-22 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| CN110996917A (zh) | 2017-05-26 | 2020-04-10 | 克雷斯顿沃控股公司 | 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法 |
| JP6840272B2 (ja) | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| MA49373B1 (fr) | 2017-06-14 | 2021-02-26 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| HRP20201629T1 (hr) | 2017-06-14 | 2020-12-25 | 4D Pharma Research Limited | Sastavi koji sadrže bakterijski soj roda megasphaera i njihove upotrebe |
| DE102017115819A1 (de) * | 2017-07-13 | 2019-01-17 | Aiden Haghikia | Mittel zur prophylaktischen und/oder unterstützenden therapeutischen Behandlung von Morbus Parkinson |
| EP3664823B1 (en) | 2017-08-07 | 2024-06-05 | Finch Therapeutics Holdings LLC | Composition for use in preventing or treating an enterococcal blood stream infection |
| WO2019152344A1 (en) * | 2018-01-30 | 2019-08-08 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating inflammation and cancer |
| KR20210016407A (ko) | 2018-06-05 | 2021-02-15 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 대사 장애 및 비알코올성 지방 간 질환의 치료를 위한 활성제 및 그 사용 방법 |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| KR20210091119A (ko) | 2018-08-17 | 2021-07-21 | 베단타 바이오사이언시즈, 인크. | 장내세균 불균형을 감소시키는 방법 및 마이크로바이옴을 회복시키는 방법 |
| WO2020069280A1 (en) | 2018-09-27 | 2020-04-02 | Crestovo Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
| JP7444459B2 (ja) * | 2018-10-04 | 2024-03-06 | 国立研究開発法人理化学研究所 | ＩＬＣ２を標的としたＩｇＡ産生誘導方法 |
| JP7677640B2 (ja) * | 2019-07-17 | 2025-05-15 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | クロストリジウム綱コンソーシアムの組成ならびに肥満、メタボリックシンドローム及び過敏性腸疾患の治療法 |
| JP2022541795A (ja) | 2019-07-19 | 2022-09-27 | フィンチ セラピューティクス ホールディングス エルエルシー | 胃腸障害の治療のための方法および産物 |
| AU2020355194A1 (en) * | 2019-09-25 | 2022-04-28 | Julius-Maximilians-Universität Würzburg | Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy |
| US12397563B2 (en) | 2023-08-24 | 2025-08-26 | Stolle Machinery Company, Llc | Automatic label creator and method for can decorating |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2383662A1 (fr) * | 1977-03-15 | 1978-10-13 | Cassenne Lab Sa | Nouvelles compositions a usage cosmetique |
| EP0029924B1 (en) | 1979-11-16 | 1984-08-15 | STEROSYNT Ltd. | 6-alpha-fluoro-16-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them |
| US5569680A (en) * | 1995-02-13 | 1996-10-29 | Trustees Of The Univ. Of Penna | Method of treating inflammatory bowel disease with tributyrin |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| CA2440474A1 (en) * | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| EP1743654A1 (en) * | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| GB0903016D0 (en) | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| JP2016530239A (ja) * | 2013-07-09 | 2016-09-29 | ピュアテック ベンチャーズ、エルエルシー | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 |
-
2014
- 2014-07-08 JP JP2016525434A patent/JP2016530239A/ja active Pending
- 2014-07-08 EP EP14822228.4A patent/EP3019181A4/en not_active Ceased
- 2014-07-08 WO PCT/US2014/045801 patent/WO2015006355A2/en not_active Ceased
- 2014-07-08 US US14/903,377 patent/US9764019B2/en active Active
-
2017
- 2017-08-18 US US15/680,629 patent/US10130695B2/en not_active Expired - Fee Related
-
2018
- 2018-10-15 US US16/160,869 patent/US20190134179A1/en not_active Abandoned
-
2019
- 2019-05-15 JP JP2019092447A patent/JP2019189609A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530239A5 (enExample) | ||
| Peloquin et al. | Mechanisms of pediatric inflammatory bowel disease | |
| Iacob et al. | Infectious threats, the intestinal barrier, and its trojan horse: dysbiosis | |
| Fleischmann et al. | Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial | |
| Chervy et al. | Adherent-Invasive E. coli: Update on the Lifestyle of a Troublemaker in Crohn’s Disease | |
| Miehlke et al. | Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis | |
| Hansen et al. | Therapeutic manipulation of the microbiome in IBD: current results and future approaches | |
| Burke et al. | Modifiable environmental factors in inflammatory bowel disease | |
| Bamias et al. | New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation | |
| Hauso et al. | 5-Aminosalicylic acid, a specific drug for ulcerative colitis | |
| JP2019189609A (ja) | 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 | |
| Regna et al. | Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo | |
| JP2018039833A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| JP2012515213A5 (enExample) | ||
| JP2015522630A5 (enExample) | ||
| Steinert et al. | Gastro-intestinal tract: The leading role of mucosal immunity | |
| Opoku et al. | Intestinal microbiome–rheumatoid arthritis crosstalk: The therapeutic role of probiotics | |
| JP2017533220A5 (enExample) | ||
| JP2022512709A (ja) | 炎症性疾患及び自己免疫疾患を処置する組成物及び方法 | |
| JP2017507142A5 (enExample) | ||
| Salvadori et al. | Microbiota, renal disease and renal transplantation | |
| JP2017519763A5 (enExample) | ||
| Bu et al. | Gut microbiota and intestinal immunity interaction in ulcerative colitis and its application in treatment |